Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin in Crohn's Disease-related Stricture
NCT02675153Unknown
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- Apr 2015
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sirolimus in Crohn's disease (2 arms), sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoint: Response rate at 24 weeks. Status: unknown.
02
Drugs
sirolimus
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02675153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675153.